How Much Does Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cost in United States of America?
The average price of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in United States of America is $45,000, the minimum price is $35,000, and the maximum price is $55,000.
Data verified by Bookimed as of November 2025, based on patient requests and official quotes from 53 clinics worldwide. Median costs are based on real invoices (2024–2025) and updated monthly. Actual prices may vary.
We're Temporarily Out of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Clinics in United States of America — Explore Trusted Options in Turkey and Save Up to 70%.
A certified medical writer with 10+ years of experience, developed Bookimed’s trusted content, backed by a Master’s in Philology and medical expert interviews worldwide.
General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.
Fast Facts about Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HIPEC involves delivering heated chemotherapy directly into the abdominal cavity to treat cancer.
Pros: HIPEC can target cancer cells more effectively within the abdomen compared to systemic chemotherapy. It has shown a 50% increase in survival rates for certain cancers.
Cons: This procedure may lead to more immediate side effects like abdominal pain and requires hospitalization for monitoring. Only suitable for cancers confined to the peritoneal cavity.
Effectiveness: 70% success rate in extending patient survival for specific peritoneal cancers.
Duration: 6-12 hours.
Recovery: 4-6 weeks.
Best for: Peritoneal carcinomatosis and abdominal tumors, especially those from colorectal and ovarian origins.